Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KDH-136
- Development stage
- Unknown
- Lead developer
- Kowa
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
KDH-136 is a small molecule cathepsin K inhibitor developed by Kowa Dental Health for the treatment of periodontitis. Cathepsin K is a lysosomal cysteine protease that plays a critical role in bone resorption by degrading type I collagen, the primary protein component of the bone matrix. In the context of periodontitis, overactivity of cathepsin K in osteoclasts leads to the destruction of alveolar bone supporting the teeth. KDH-136 is designed to be applied locally as a dental ointment into the periodontal pocket to inhibit bone loss and promote the stabilization of dental structures. While it reached Phase 2 clinical trials in Japan, development appears to have been discontinued as it is no longer listed in the developer's active pipeline.
Beyond the preview
Go deeper on KDH-136.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KDH-136.